Ehlers-Danlos syndrome musculocontractural type 2

Summary
Definition
An Ehlers-Danlos syndrome that is characterized by progressive multisystem fragility-related manifestations, including joint dislocations and deformities; skin hyperextensibility, bruisability, and fragility, with recurrent large subcutaneous hematomas; cardiac valvular, respiratory, gastrointestinal, and ophthalmologic complications; and myopathy, featuring muscle hypoplasia, muscle weakness, and an abnormal muscle fiber pattern in histology in adulthood, resulting in gross motor developmental delay and that has_material_basis_in homozygous mutation in the DSE gene on chromosome 6q22.
Super Class
Ehlers-Danlos syndrome autosomal recessive disease
Disease Ontology
DOID:0080737
Mondo Disease Ontology
OMIM
Related Genes
Displaying 1 entry
Gene ID Gene Symbol Description Source
29940 DSE dermatan sulfate epimerase
Displaying 1 entry
Gene ID Gene Symbol Description Source
212898 Dse dermatan sulfate epimerase
The Human Phenotype Ontology
Displaying entries 61 - 70 of 85 in total
HPO ID HPO Term
HP:0100016 Abnormal mesentery morphology
HP:0001166 Arachnodactyly
HP:0003577 Congenital onset
HP:0001776 Bilateral talipes equinovarus
HP:0001634 Mitral valve prolapse
HP:0002829 Arthralgia
HP:0001655 Patent foramen ovale
HP:0000297 Facial hypotonia
HP:0003324 Generalized muscle weakness
HP:0001058 Poor wound healing
Displaying all 2 entries
Gene ID Gene Symbol Description
113189 CHST14 carbohydrate sulfotransferase 14
29940 DSE dermatan sulfate epimerase

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.1.0

Last updated: December 9, 2024